Searched for
DRUG FIRM LUPIN
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...
- Time to buy? Sunny Agrawal finds best picks across banking, pharma, capital markets & infrastructureIndian stock markets present attractive opportunities now. Investors with an 18-month outlook should consider deploying funds, especially i...
- Lupin seeks strategic partnerships for long-acting injectable platformDrug firm Lupin has launched a strategic partnership program to expand the reach of its subsidiary Nanomi BV's long-acting injectable platf...
- Lupin gets USFDA nod for generic HIV drugDrug firm Lupin on Tuesday said it has received an approval from the US health regulator to market Darunavir Tablets, used to treat Human I...
- Lupin gets USFDA nod to market generic drugThe company has received approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA), Vigabatri...
- Lupin launches generic drug in the US marketThe Mumbai-based drug firm's product is the generic equivalent of Zyla Life Sciences' Vivlodex Capsules (5 mg and 10 mg). The capsules are ...
- Lupin Q4 results: Net profit rises 35% to Rs 390 croreConsolidated income from operations of the company stood at Rs 3,791 crore for the quarter under consideration as against Rs 3,807.02 crore...
- USFDA issues 2 observations after inspection of Lupin's Pithampur unitThe inspection of the company's Pithampur Unit-I facility by the USFDA has been completed.
- USFDA finds minor violations at Lupin's Dabhasa plantDrug firm Lupin today said US health regulator has voiced minor concerns after completing the inspection of its Dabhasa facility in Gujarat.
- Lupin receives USFDA nod for Lorazepam Oral ConcentrateDrug firm Lupin said it has received US health regulator's approval to market its generic Lorazepam Oral Concentrate in American market.
- Lupin launches generic Tricor in the USLupin has launched generic version of Tricor in the US market after getting approval from the US Food and Drug Administration.
- Lupin gets USFDA nod to market generic contraceptive tabletsDrug firm Lupin today said it has received final approval from the US health regulator to market its generic Levonorgestrel and Ethinyl Est...
- Lupin gets USFDA approval for oral contraceptive tablets KurveloDrug firm Lupin today said its subsidiary has received American health regulator's approval to market its generic oral contraceptive tablet...
- Lupin gets USFDA approval for generic version of LyricaDrug firm Lupin today said it has received approval from the US health regulator to market generic version of Lyrica in the American market.
- Lupin resumes anti-diabetic drug sales in US after court nodIn December last year, Shionogi's request for a preliminary injunction had been granted and had blocked Lupin from further sales of the pro...
- Lupin, Natco tie up to market breast cancer tabletsDrug firms Lupin Ltd and Natco Pharma today said that they have entered into an alliance to jointly market generic Lapatinib Ditosylate tab...
- Lupin inks pact with Brazil for TB drug supply for 5 yrsDrug firm Lupin today said it has signed an agreement with Brazil to supply its four-in-one combination drug to treat tuberculosis.
- Lupin gets FDA nod for anti-allergic tabletsDrug firm Lupin today said it has been granted final approval by the United states Food and Drug Administration for antihistamine Deslorata...
Load More
